Alexander Höllein

544 total citations
14 papers, 209 citations indexed

About

Alexander Höllein is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Alexander Höllein has authored 14 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Alexander Höllein's work include Acute Myeloid Leukemia Research (6 papers), Single-cell and spatial transcriptomics (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Alexander Höllein is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Single-cell and spatial transcriptomics (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Alexander Höllein collaborates with scholars based in Germany, Italy and Switzerland. Alexander Höllein's co-authors include Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Manja Meggendorfer, Niroshan Nadarajah, Sabine Jeromin, Frank Dicker, Peter Krawitz, F. Elsner and Richard Schabath and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Alexander Höllein

13 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexander Höllein Germany	7	124	91	61	47	31	14	209
Chi‐Yuan Yao Taiwan	9	129 1.0×	119 1.3×	69 1.1×	59 1.3×	14 0.5×	38	253
Adrián Mosquera Orgueira Spain	10	109 0.9×	130 1.4×	45 0.7×	40 0.9×	17 0.5×	32	263
Nikolaos Sousos United Kingdom	7	162 1.3×	192 2.1×	82 1.3×	125 2.7×	31 1.0×	15	362
José Ángel Díaz Arias Spain	9	67 0.5×	99 1.1×	38 0.6×	30 0.6×	16 0.5×	20	184
Christian Pohlkamp Germany	7	69 0.6×	32 0.4×	29 0.5×	42 0.9×	27 0.9×	18	151
Askar Obulkasim Netherlands	9	52 0.4×	137 1.5×	98 1.6×	10 0.2×	11 0.4×	15	241
Costa Bachas Netherlands	10	256 2.1×	211 2.3×	77 1.3×	56 1.2×	12 0.4×	23	422
Xianglan Lu United States	7	43 0.3×	78 0.9×	16 0.3×	28 0.6×	14 0.5×	29	161
Metis Hasipek United States	9	102 0.8×	188 2.1×	25 0.4×	23 0.5×	7 0.2×	26	272
Sunisa Kongkiatkamon United States	6	101 0.8×	33 0.4×	13 0.2×	72 1.5×	8 0.3×	30	178

Countries citing papers authored by Alexander Höllein

Since Specialization

Citations

This map shows the geographic impact of Alexander Höllein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Höllein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Höllein more than expected).

Fields of papers citing papers by Alexander Höllein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Höllein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Höllein. The network helps show where Alexander Höllein may publish in the future.

Co-authorship network of co-authors of Alexander Höllein

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Höllein. A scholar is included among the top collaborators of Alexander Höllein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Höllein. Alexander Höllein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Casuscelli, Jozefina, Thomas Büttner, Christopher Darr, et al.. (2025). Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).. Journal of Clinical Oncology. 43(5_suppl). 715–715.

Klümper, Niklas, Thomas Büttner, Alexander Höllein, et al.. (2024). Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.. Journal of Clinical Oncology. 42(4_suppl). 553–553. 1 indexed citations

Meintker, Lisa, Alexander Höllein, F. Elsner, et al.. (2021). Knowledge transfer to enhance the performance of deep learning models for automated classification of B cell neoplasms. Patterns. 2(10). 100351–100351. 18 indexed citations

Cappelli, Luca Vincenzo, Manja Meggendorfer, Constance Baer, et al.. (2021). Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration. Leukemia. 36(2). 394–402. 23 indexed citations

Höllein, Alexander, Peter Bojko, Sebastian Schulz, et al.. (2021). Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study. Acta Oncologica. 60(1). 24–27. 6 indexed citations

Höllein, Alexander, Sven Twardziok, Wencke Walter, et al.. (2020). The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?. Cancer Genetics. 242. 15–24. 22 indexed citations

Höllein, Alexander, Richard Schabath, Claudia Haferlach, et al.. (2020). Hematologist‐Level Classification of Mature B‐Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data. Cytometry Part A. 97(10). 1073–1080. 44 indexed citations

Hartmann, Luise, Niroshan Nadarajah, Manja Meggendorfer, et al.. (2019). Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia. Leukemia. 34(3). 811–820. 5 indexed citations

Höllein, Alexander, Niroshan Nadarajah, Manja Meggendorfer, et al.. (2019). Molecular characterization of AML with RUNX1‐RUNX1T1 at diagnosis and relapse reveals net loss of co‐mutations. HemaSphere. 3(1). e178–e178. 11 indexed citations

10.

Höllein, Alexander, Sabine Jeromin, Manja Meggendorfer, et al.. (2018). Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. Leukemia. 32(10). 2270–2274. 17 indexed citations

11.

Höllein, Alexander, Manja Meggendorfer, Frank Dicker, et al.. (2018). NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Advances. 2(22). 3118–3125. 53 indexed citations

12.

Cappelli, Luca Vincenzo, Manja Meggendorfer, Constance Baer, et al.. (2018). NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis. Blood. 132(Supplement 1). 996–996. 1 indexed citations

13.

Höllein, Alexander, Richard Schabath, Torsten Haferlach, et al.. (2018). An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma. Blood. 132(Supplement 1). 2856–2856. 5 indexed citations

14.

Höllein, Alexander, Anna Stengel, Manja Meggendorfer, et al.. (2017). Deletion 7q Is Associated with KLF2 and NOTCH2 Mutations and Is Strongly Correlated with Splenic Marginal Zone Lymphoma but Also Found in Lymphoplasmacytic Lymphoma and Hairy Cell Leukemia Variant. Blood. 130. 1465–1465. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact